An observational study in Hepatocellular Carcinoma, HIV and Chronic Hepatitis C, sponsored by Hospital Universitario de Valme. Completed at 30 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-16.
Sponsored by Hospital Universitario de Valme · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Carcinoma, Hepatocellular with a site in Spain — 24 open to participants now, 49 under way, 13 of them phase 3. Carcinoma, Hepatocellular · Spain.
Among the 162 studies in Carcinoma, Hepatocellular with a site in Spain, this one is the 9th largest by enrollment of the 21 observational ones that give a count, is one of 4 that started in 2014, is one of 21 observational ones, and was the 61st registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →24 of the 162 studies in Carcinoma, Hepatocellular with a site in Spain are open now. Recruiting first, the newest first:
Fundacion Clinic per a la Recerca Biomédica · Sites in Spain
Ages 18+
CatalYm GmbH · Sites in Spain, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Spain, United States, Australia and 11 more countries
Ages 18+
Zymeworks BC Inc. · Sites in Spain, United States, Ireland and 3 more countries
Ages 18+
Philipp Dutkowski · Sites in Spain, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 61 · Phase 3 40 · Phase 4 3
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 477 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 145 across the 141 interventional studies, 417 across the 21 observational. Of the 106 that completed or were terminated, 55 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 162 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario de Valme is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Hospital Universitario de Valme has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
15 of the studies in Carcinoma, Hepatocellular with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 162 studies in Carcinoma, Hepatocellular with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Observational study. All HIV-infected patients who have been diagnosed of hepatocellular carcinoma (HCC), following the American Association for the Study of Liver Diseases (AASLD) criteria, in the participant centers are included. Epidemiological, clinical and laboratory data are collected. The clinical and epidemiological characteristics of HCC cases will be analyzed. The efficacy and outcomes after modalities of HCC therapy will be assessed. Mortality and its predictors will be also assessed. In those cases infected by hepatitis C virus (HCV), the impact of HCV therapy on outcomes will be analysed.
HIV-infected patients who are diagnosed of hepatocellular carcinoma following AASLD criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall survival
Overall survival after HCC diagnosis at 1 year
Time frame: At 1 year
Plan to share: No
The record gives a start of May 2014, a primary completion of Jun 2021 and a completion of Jun 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario de Valme